nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP1A2—chronic obstructive pulmonary disease	0.398	1	CbGaD
Aprepitant—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0473	0.129	CbGbCtD
Aprepitant—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0473	0.129	CbGbCtD
Aprepitant—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0393	0.107	CbGbCtD
Aprepitant—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0393	0.107	CbGbCtD
Aprepitant—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0371	0.101	CbGbCtD
Aprepitant—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0302	0.0822	CbGbCtD
Aprepitant—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0298	0.0812	CbGbCtD
Aprepitant—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0204	0.0555	CbGbCtD
Aprepitant—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0199	0.0541	CbGbCtD
Aprepitant—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0194	0.053	CbGbCtD
Aprepitant—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0173	0.0472	CbGbCtD
Aprepitant—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0102	0.0277	CbGbCtD
Aprepitant—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0096	0.0262	CbGbCtD
Aprepitant—TACR3—smooth muscle tissue—chronic obstructive pulmonary disease	0.0023	0.298	CbGeAlD
Aprepitant—TACR1—respiratory system—chronic obstructive pulmonary disease	0.00111	0.143	CbGeAlD
Aprepitant—TACR1—connective tissue—chronic obstructive pulmonary disease	0.000975	0.126	CbGeAlD
Aprepitant—TACR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000892	0.115	CbGeAlD
Aprepitant—TACR1—trachea—chronic obstructive pulmonary disease	0.000819	0.106	CbGeAlD
Aprepitant—TACR1—lung—chronic obstructive pulmonary disease	0.000588	0.0761	CbGeAlD
Aprepitant—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000346	0.0447	CbGeAlD
Aprepitant—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000333	0.0431	CbGeAlD
Aprepitant—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00121	CcSEcCtD
Aprepitant—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00121	CcSEcCtD
Aprepitant—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000201	0.00121	CcSEcCtD
Aprepitant—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00121	CcSEcCtD
Aprepitant—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.0002	0.00121	CcSEcCtD
Aprepitant—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.0002	0.00121	CcSEcCtD
Aprepitant—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.0002	0.0012	CcSEcCtD
Aprepitant—Oedema—Montelukast—chronic obstructive pulmonary disease	0.0002	0.0012	CcSEcCtD
Aprepitant—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.0002	0.0012	CcSEcCtD
Aprepitant—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Aprepitant—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000199	0.0012	CcSEcCtD
Aprepitant—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.0012	CcSEcCtD
Aprepitant—Infection—Montelukast—chronic obstructive pulmonary disease	0.000198	0.0012	CcSEcCtD
Aprepitant—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.00119	CcSEcCtD
Aprepitant—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.00119	CcSEcCtD
Aprepitant—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000198	0.00119	CcSEcCtD
Aprepitant—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000197	0.00119	CcSEcCtD
Aprepitant—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00118	CcSEcCtD
Aprepitant—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000196	0.00118	CcSEcCtD
Aprepitant—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000196	0.00118	CcSEcCtD
Aprepitant—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00118	CcSEcCtD
Aprepitant—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000194	0.00117	CcSEcCtD
Aprepitant—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000193	0.00116	CcSEcCtD
Aprepitant—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00116	CcSEcCtD
Aprepitant—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00116	CcSEcCtD
Aprepitant—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00115	CcSEcCtD
Aprepitant—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00115	CcSEcCtD
Aprepitant—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00115	CcSEcCtD
Aprepitant—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00019	0.00114	CcSEcCtD
Aprepitant—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000189	0.00114	CcSEcCtD
Aprepitant—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000189	0.00114	CcSEcCtD
Aprepitant—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000189	0.00114	CcSEcCtD
Aprepitant—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000189	0.00114	CcSEcCtD
Aprepitant—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.00113	CcSEcCtD
Aprepitant—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000188	0.00113	CcSEcCtD
Aprepitant—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00113	CcSEcCtD
Aprepitant—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000186	0.00112	CcSEcCtD
Aprepitant—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00112	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00112	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00112	CcSEcCtD
Aprepitant—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.00111	CcSEcCtD
Aprepitant—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000184	0.00111	CcSEcCtD
Aprepitant—CYP1A2—lung—chronic obstructive pulmonary disease	0.000184	0.0237	CbGeAlD
Aprepitant—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00111	CcSEcCtD
Aprepitant—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000183	0.0011	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000182	0.0011	CcSEcCtD
Aprepitant—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000182	0.0011	CcSEcCtD
Aprepitant—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000182	0.0011	CcSEcCtD
Aprepitant—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Aprepitant—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Aprepitant—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000181	0.00109	CcSEcCtD
Aprepitant—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00108	CcSEcCtD
Aprepitant—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Aprepitant—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Aprepitant—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Aprepitant—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000179	0.00108	CcSEcCtD
Aprepitant—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000178	0.00107	CcSEcCtD
Aprepitant—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000177	0.00107	CcSEcCtD
Aprepitant—CYP3A5—lung—chronic obstructive pulmonary disease	0.000177	0.0229	CbGeAlD
Aprepitant—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.00107	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.00106	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000176	0.00106	CcSEcCtD
Aprepitant—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00106	CcSEcCtD
Aprepitant—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.00106	CcSEcCtD
Aprepitant—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000176	0.00106	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00106	CcSEcCtD
Aprepitant—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Aprepitant—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Aprepitant—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Aprepitant—Pain—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Aprepitant—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.00105	CcSEcCtD
Aprepitant—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00104	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000172	0.00104	CcSEcCtD
Aprepitant—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000172	0.00104	CcSEcCtD
Aprepitant—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00103	CcSEcCtD
Aprepitant—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00103	CcSEcCtD
Aprepitant—Pain—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00103	CcSEcCtD
Aprepitant—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.00103	CcSEcCtD
Aprepitant—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00017	0.00103	CcSEcCtD
Aprepitant—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.00017	0.00102	CcSEcCtD
Aprepitant—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.00017	0.00102	CcSEcCtD
Aprepitant—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00102	CcSEcCtD
Aprepitant—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000169	0.00102	CcSEcCtD
Aprepitant—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000169	0.00102	CcSEcCtD
Aprepitant—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000168	0.00101	CcSEcCtD
Aprepitant—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00101	CcSEcCtD
Aprepitant—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00101	CcSEcCtD
Aprepitant—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000168	0.00101	CcSEcCtD
Aprepitant—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00101	CcSEcCtD
Aprepitant—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.00101	CcSEcCtD
Aprepitant—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.001	CcSEcCtD
Aprepitant—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000167	0.001	CcSEcCtD
Aprepitant—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000167	0.001	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.001	CcSEcCtD
Aprepitant—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.001	CcSEcCtD
Aprepitant—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.000992	CcSEcCtD
Aprepitant—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.000992	CcSEcCtD
Aprepitant—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000163	0.000984	CcSEcCtD
Aprepitant—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000984	CcSEcCtD
Aprepitant—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.000976	CcSEcCtD
Aprepitant—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000162	0.000976	CcSEcCtD
Aprepitant—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Aprepitant—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Aprepitant—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Aprepitant—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000971	CcSEcCtD
Aprepitant—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000161	0.000968	CcSEcCtD
Aprepitant—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000159	0.00096	CcSEcCtD
Aprepitant—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000159	0.000959	CcSEcCtD
Aprepitant—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000159	0.000959	CcSEcCtD
Aprepitant—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000159	0.000956	CcSEcCtD
Aprepitant—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.000956	CcSEcCtD
Aprepitant—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000158	0.000954	CcSEcCtD
Aprepitant—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000158	0.000954	CcSEcCtD
Aprepitant—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000952	CcSEcCtD
Aprepitant—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000952	CcSEcCtD
Aprepitant—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.000949	CcSEcCtD
Aprepitant—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000922	CcSEcCtD
Aprepitant—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000917	CcSEcCtD
Aprepitant—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000917	CcSEcCtD
Aprepitant—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00015	0.000905	CcSEcCtD
Aprepitant—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.000905	CcSEcCtD
Aprepitant—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00015	0.000904	CcSEcCtD
Aprepitant—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000896	CcSEcCtD
Aprepitant—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000147	0.000887	CcSEcCtD
Aprepitant—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000146	0.000882	CcSEcCtD
Aprepitant—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000146	0.000882	CcSEcCtD
Aprepitant—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000144	0.000869	CcSEcCtD
Aprepitant—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000144	0.000869	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000868	CcSEcCtD
Aprepitant—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000868	CcSEcCtD
Aprepitant—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000143	0.000864	CcSEcCtD
Aprepitant—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000856	CcSEcCtD
Aprepitant—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.000855	CcSEcCtD
Aprepitant—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000141	0.000852	CcSEcCtD
Aprepitant—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.000841	CcSEcCtD
Aprepitant—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000139	0.000841	CcSEcCtD
Aprepitant—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000833	CcSEcCtD
Aprepitant—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000828	CcSEcCtD
Aprepitant—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000137	0.000824	CcSEcCtD
Aprepitant—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000136	0.000821	CcSEcCtD
Aprepitant—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.000815	CcSEcCtD
Aprepitant—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.000813	CcSEcCtD
Aprepitant—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000135	0.000813	CcSEcCtD
Aprepitant—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000796	CcSEcCtD
Aprepitant—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000795	CcSEcCtD
Aprepitant—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000794	CcSEcCtD
Aprepitant—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00013	0.000781	CcSEcCtD
Aprepitant—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.000781	CcSEcCtD
Aprepitant—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.000775	CcSEcCtD
Aprepitant—Rash—Formoterol—chronic obstructive pulmonary disease	0.000129	0.000775	CcSEcCtD
Aprepitant—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000774	CcSEcCtD
Aprepitant—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000774	CcSEcCtD
Aprepitant—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000774	CcSEcCtD
Aprepitant—Headache—Formoterol—chronic obstructive pulmonary disease	0.000128	0.00077	CcSEcCtD
Aprepitant—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.00077	CcSEcCtD
Aprepitant—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000769	CcSEcCtD
Aprepitant—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000767	CcSEcCtD
Aprepitant—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000767	CcSEcCtD
Aprepitant—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000127	0.000765	CcSEcCtD
Aprepitant—Rash—Montelukast—chronic obstructive pulmonary disease	0.000126	0.000759	CcSEcCtD
Aprepitant—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000126	0.000758	CcSEcCtD
Aprepitant—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000757	CcSEcCtD
Aprepitant—Headache—Montelukast—chronic obstructive pulmonary disease	0.000125	0.000754	CcSEcCtD
Aprepitant—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000748	CcSEcCtD
Aprepitant—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000745	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000123	0.00201	CbGpPWpGaD
Aprepitant—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000743	CcSEcCtD
Aprepitant—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000743	CcSEcCtD
Aprepitant—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000738	CcSEcCtD
Aprepitant—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000122	0.000735	CcSEcCtD
Aprepitant—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000732	CcSEcCtD
Aprepitant—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000731	CcSEcCtD
Aprepitant—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000731	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000121	0.00197	CbGpPWpGaD
Aprepitant—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000121	0.00073	CcSEcCtD
Aprepitant—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000121	0.00073	CcSEcCtD
Aprepitant—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000727	CcSEcCtD
Aprepitant—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00012	0.00196	CbGpPWpGaD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00012	0.00195	CbGpPWpGaD
Aprepitant—CYP3A7—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000119	0.00195	CbGpPWpGaD
Aprepitant—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000717	CcSEcCtD
Aprepitant—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000119	0.000715	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	0.000117	0.00191	CbGpPWpGaD
Aprepitant—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000707	CcSEcCtD
Aprepitant—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.0019	CbGpPWpGaD
Aprepitant—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000704	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000116	0.00189	CbGpPWpGaD
Aprepitant—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000693	CcSEcCtD
Aprepitant—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.000689	CcSEcCtD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000114	0.00186	CbGpPWpGaD
Aprepitant—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000686	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000113	0.00185	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000113	0.00184	CbGpPWpGaD
Aprepitant—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00184	CbGpPWpGaD
Aprepitant—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000677	CcSEcCtD
Aprepitant—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000669	CcSEcCtD
Aprepitant—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000666	CcSEcCtD
Aprepitant—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000666	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.00179	CbGpPWpGaD
Aprepitant—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.00179	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.00179	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000109	0.00178	CbGpPWpGaD
Aprepitant—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000655	CcSEcCtD
Aprepitant—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000108	0.00177	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000108	0.00176	CbGpPWpGaD
Aprepitant—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.00065	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	0.000107	0.00175	CbGpPWpGaD
Aprepitant—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.000107	0.00175	CbGpPWpGaD
Aprepitant—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000643	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000106	0.00173	CbGpPWpGaD
Aprepitant—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000636	CcSEcCtD
Aprepitant—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000105	0.00172	CbGpPWpGaD
Aprepitant—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000632	CcSEcCtD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.0017	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000104	0.0017	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00168	CbGpPWpGaD
Aprepitant—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00167	CbGpPWpGaD
Aprepitant—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000618	CcSEcCtD
Aprepitant—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000615	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000101	0.00165	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.99e-05	0.00163	CbGpPWpGaD
Aprepitant—Insomnia—Prednisolone—chronic obstructive pulmonary disease	9.99e-05	0.000602	CcSEcCtD
Aprepitant—Alopecia—Prednisone—chronic obstructive pulmonary disease	9.98e-05	0.000602	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.96e-05	0.00162	CbGpPWpGaD
Aprepitant—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	9.91e-05	0.000598	CcSEcCtD
Aprepitant—Mental disorder—Prednisone—chronic obstructive pulmonary disease	9.89e-05	0.000596	CcSEcCtD
Aprepitant—Erythema—Prednisone—chronic obstructive pulmonary disease	9.83e-05	0.000593	CcSEcCtD
Aprepitant—Malnutrition—Prednisone—chronic obstructive pulmonary disease	9.83e-05	0.000593	CcSEcCtD
Aprepitant—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	9.67e-05	0.00157	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	9.45e-05	0.00154	CbGpPWpGaD
Aprepitant—Pain—Prednisolone—chronic obstructive pulmonary disease	9.44e-05	0.000569	CcSEcCtD
Aprepitant—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	9.33e-05	0.00152	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.29e-05	0.00151	CbGpPWpGaD
Aprepitant—CYP3A7—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.28e-05	0.00151	CbGpPWpGaD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.26e-05	0.00151	CbGpPWpGaD
Aprepitant—CYP3A7—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9.16e-05	0.00149	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	9.12e-05	0.00055	CcSEcCtD
Aprepitant—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.1e-05	0.000548	CcSEcCtD
Aprepitant—Anaemia—Prednisone—chronic obstructive pulmonary disease	9.09e-05	0.000548	CcSEcCtD
Aprepitant—Angioedema—Prednisone—chronic obstructive pulmonary disease	8.98e-05	0.000541	CcSEcCtD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.9e-05	0.00145	CbGpPWpGaD
Aprepitant—Malaise—Prednisone—chronic obstructive pulmonary disease	8.87e-05	0.000534	CcSEcCtD
Aprepitant—Syncope—Prednisone—chronic obstructive pulmonary disease	8.82e-05	0.000531	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.8e-05	0.00143	CbGpPWpGaD
Aprepitant—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.78e-05	0.00143	CbGpPWpGaD
Aprepitant—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.77e-05	0.000529	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	8.76e-05	0.00143	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.75e-05	0.00143	CbGpPWpGaD
Aprepitant—CYP3A7—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.68e-05	0.00141	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	8.64e-05	0.00141	CbGpPWpGaD
Aprepitant—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	8.64e-05	0.000521	CcSEcCtD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.63e-05	0.00141	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	8.59e-05	0.0014	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.57e-05	0.0014	CbGpPWpGaD
Aprepitant—Convulsion—Prednisone—chronic obstructive pulmonary disease	8.52e-05	0.000513	CcSEcCtD
Aprepitant—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	8.49e-05	0.00138	CbGpPWpGaD
Aprepitant—Hypertension—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000512	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.44e-05	0.00138	CbGpPWpGaD
Aprepitant—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.37e-05	0.000504	CcSEcCtD
Aprepitant—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.37e-05	0.000504	CcSEcCtD
Aprepitant—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.34e-05	0.000503	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.31e-05	0.000501	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	8.28e-05	0.00135	CbGpPWpGaD
Aprepitant—Discomfort—Prednisone—chronic obstructive pulmonary disease	8.27e-05	0.000498	CcSEcCtD
Aprepitant—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.14e-05	0.00133	CbGpPWpGaD
Aprepitant—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	8.13e-05	0.00049	CcSEcCtD
Aprepitant—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.05e-05	0.00131	CbGpPWpGaD
Aprepitant—Oedema—Prednisone—chronic obstructive pulmonary disease	8.02e-05	0.000484	CcSEcCtD
Aprepitant—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	8.02e-05	0.000484	CcSEcCtD
Aprepitant—Infection—Prednisone—chronic obstructive pulmonary disease	7.97e-05	0.00048	CcSEcCtD
Aprepitant—Shock—Prednisone—chronic obstructive pulmonary disease	7.89e-05	0.000476	CcSEcCtD
Aprepitant—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	7.87e-05	0.000474	CcSEcCtD
Aprepitant—Tachycardia—Prednisone—chronic obstructive pulmonary disease	7.83e-05	0.000472	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	7.8e-05	0.00127	CbGpPWpGaD
Aprepitant—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.79e-05	0.00047	CcSEcCtD
Aprepitant—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000468	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.72e-05	0.00126	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	7.66e-05	0.00125	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.66e-05	0.00125	CbGpPWpGaD
Aprepitant—Anorexia—Prednisone—chronic obstructive pulmonary disease	7.65e-05	0.000461	CcSEcCtD
Aprepitant—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	7.52e-05	0.00122	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.43e-05	0.00121	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.34e-05	0.0012	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.31e-05	0.000441	CcSEcCtD
Aprepitant—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.3e-05	0.00119	CbGpPWpGaD
Aprepitant—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.3e-05	0.00044	CcSEcCtD
Aprepitant—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.26e-05	0.000437	CcSEcCtD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.21e-05	0.00118	CbGpPWpGaD
Aprepitant—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	7.2e-05	0.000434	CcSEcCtD
Aprepitant—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.2e-05	0.00117	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	7.09e-05	0.00115	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—APIP—chronic obstructive pulmonary disease	7.08e-05	0.00115	CbGpPWpGaD
Aprepitant—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.06e-05	0.000426	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.01e-05	0.00114	CbGpPWpGaD
Aprepitant—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.97e-05	0.00042	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	6.97e-05	0.00114	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.96e-05	0.00113	CbGpPWpGaD
Aprepitant—Rash—Prednisolone—chronic obstructive pulmonary disease	6.96e-05	0.00042	CcSEcCtD
Aprepitant—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.95e-05	0.000419	CcSEcCtD
Aprepitant—Fatigue—Prednisone—chronic obstructive pulmonary disease	6.92e-05	0.000417	CcSEcCtD
Aprepitant—Headache—Prednisolone—chronic obstructive pulmonary disease	6.92e-05	0.000417	CcSEcCtD
Aprepitant—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	6.91e-05	0.00113	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.87e-05	0.00112	CbGpPWpGaD
Aprepitant—Constipation—Prednisone—chronic obstructive pulmonary disease	6.86e-05	0.000414	CcSEcCtD
Aprepitant—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.78e-05	0.0011	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.77e-05	0.0011	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.71e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.7e-05	0.00109	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.68e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.67e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	6.67e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	6.64e-05	0.00108	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.62e-05	0.00108	CbGpPWpGaD
Aprepitant—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.61e-05	0.000399	CcSEcCtD
Aprepitant—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.56e-05	0.000395	CcSEcCtD
Aprepitant—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.56e-05	0.000395	CcSEcCtD
Aprepitant—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.37e-05	0.000384	CcSEcCtD
Aprepitant—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.36e-05	0.00104	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.35e-05	0.00103	CbGpPWpGaD
Aprepitant—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.34e-05	0.000382	CcSEcCtD
Aprepitant—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.34e-05	0.000382	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	6.33e-05	0.00103	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.27e-05	0.00102	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.27e-05	0.00102	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.23e-05	0.00101	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.17e-05	0.00101	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	6.1e-05	0.000994	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	6.09e-05	0.000992	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.09e-05	0.000992	CbGpPWpGaD
Aprepitant—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.91e-05	0.000356	CcSEcCtD
Aprepitant—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.76e-05	0.000347	CcSEcCtD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.72e-05	0.000933	CbGpPWpGaD
Aprepitant—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.68e-05	0.000342	CcSEcCtD
Aprepitant—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.65e-05	0.00092	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.57e-05	0.000907	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.57e-05	0.000907	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	5.54e-05	0.000902	CbGpPWpGaD
Aprepitant—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.000331	CcSEcCtD
Aprepitant—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.31e-05	0.00032	CcSEcCtD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.22e-05	0.00085	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.19e-05	0.000845	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	5.16e-05	0.00084	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.15e-05	0.000838	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.12e-05	0.000834	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	5.12e-05	0.000834	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.12e-05	0.000833	CbGpPWpGaD
Aprepitant—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.1e-05	0.000307	CcSEcCtD
Aprepitant—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.08e-05	0.000827	CbGpPWpGaD
Aprepitant—Rash—Prednisone—chronic obstructive pulmonary disease	5.06e-05	0.000305	CcSEcCtD
Aprepitant—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.05e-05	0.000305	CcSEcCtD
Aprepitant—Headache—Prednisone—chronic obstructive pulmonary disease	5.03e-05	0.000303	CcSEcCtD
Aprepitant—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.92e-05	0.000801	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.9e-05	0.000798	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.89e-05	0.000796	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.88e-05	0.000795	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.85e-05	0.00079	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.84e-05	0.000789	CbGpPWpGaD
Aprepitant—Nausea—Prednisone—chronic obstructive pulmonary disease	4.77e-05	0.000287	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.73e-05	0.000771	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.73e-05	0.000771	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.69e-05	0.000764	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.67e-05	0.00076	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.67e-05	0.00076	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.64e-05	0.000756	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.64e-05	0.000756	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	4.56e-05	0.000743	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.54e-05	0.000739	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.48e-05	0.00073	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.46e-05	0.000727	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.42e-05	0.00072	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.42e-05	0.00072	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.42e-05	0.00072	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.4e-05	0.000717	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.34e-05	0.000707	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.24e-05	0.000691	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.19e-05	0.000682	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.14e-05	0.000674	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.07e-05	0.000663	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.04e-05	0.000658	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.01e-05	0.000654	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.99e-05	0.000649	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	3.96e-05	0.000644	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.94e-05	0.000641	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.83e-05	0.000624	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.78e-05	0.000616	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.77e-05	0.000614	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.74e-05	0.00061	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.74e-05	0.000609	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.61e-05	0.000588	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.42e-05	0.000557	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.4e-05	0.000554	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.39e-05	0.000553	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.39e-05	0.000552	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.36e-05	0.000548	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.35e-05	0.000545	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	3.3e-05	0.000537	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.27e-05	0.000533	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.12e-05	0.000508	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.09e-05	0.000503	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.08e-05	0.000502	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.08e-05	0.000501	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.07e-05	0.000499	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.04e-05	0.000496	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.03e-05	0.000493	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.96e-05	0.000482	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.92e-05	0.000475	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.82e-05	0.00046	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.62e-05	0.000427	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.6e-05	0.000423	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.57e-05	0.000419	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.55e-05	0.000415	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.54e-05	0.000414	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.5e-05	0.000407	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.49e-05	0.000406	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	2.46e-05	0.000401	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.39e-05	0.000389	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.39e-05	0.000389	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.38e-05	0.000388	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.37e-05	0.000386	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.37e-05	0.000386	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.33e-05	0.000379	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.32e-05	0.000379	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.28e-05	0.000371	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	2.25e-05	0.000366	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.2e-05	0.000358	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.16e-05	0.000352	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.07e-05	0.000337	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.04e-05	0.000333	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.02e-05	0.000329	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.99e-05	0.000324	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.92e-05	0.000313	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.89e-05	0.000308	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.85e-05	0.000301	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.83e-05	0.000298	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.8e-05	0.000293	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.78e-05	0.00029	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.73e-05	0.000281	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.72e-05	0.00028	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.7e-05	0.000278	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.64e-05	0.000267	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.63e-05	0.000265	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.59e-05	0.000259	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.58e-05	0.000257	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.53e-05	0.00025	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.51e-05	0.000245	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.5e-05	0.000245	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.5e-05	0.000244	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.48e-05	0.000241	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.47e-05	0.00024	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.43e-05	0.000232	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.39e-05	0.000227	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.38e-05	0.000224	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.28e-05	0.000209	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.27e-05	0.000207	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.26e-05	0.000205	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.26e-05	0.000204	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.25e-05	0.000203	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.24e-05	0.000202	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.23e-05	0.000201	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.17e-05	0.000191	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.16e-05	0.000189	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.15e-05	0.000187	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.15e-05	0.000187	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.14e-05	0.000185	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.09e-05	0.000177	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.09e-05	0.000177	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.07e-05	0.000175	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.06e-05	0.000172	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	1.02e-05	0.000167	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1e-05	0.000163	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.79e-06	0.000159	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	9.79e-06	0.000159	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.65e-06	0.000157	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.52e-06	0.000155	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.87e-06	0.000145	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.8e-06	0.000143	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.68e-06	0.000141	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.41e-06	0.000137	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.38e-06	0.000136	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.28e-06	0.000135	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.09e-06	0.000132	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.67e-06	0.000125	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	7.55e-06	0.000123	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.52e-06	0.000123	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.42e-06	0.000121	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	7.39e-06	0.00012	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	7.07e-06	0.000115	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.96e-06	0.000113	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.91e-06	0.000113	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.55e-06	0.000107	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.81e-06	9.46e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.73e-06	9.33e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	5.72e-06	9.31e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	5.47e-06	8.91e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.33e-06	8.69e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	5.21e-06	8.49e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.06e-06	8.24e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	4.99e-06	8.12e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.45e-06	7.26e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.26e-06	6.94e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.44e-06	5.6e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.29e-06	5.36e-05	CbGpPWpGaD
